CME: Practical Considerations on the Use of Immune Checkpoint Inhibitors & Chemotherapy in mNSCLC

Practical Considerations on the Use of Immune Checkpoint Inhibitors & Chemotherapy in mNSCLC

Practical Considerations on the Use of Immune Checkpoint Inhibitors & Chemotherapy in mNSCLC

As immunotherapies change the treatment landscape in advanced non-small cell lung cancer, does PD-L1 status still matter in determining therapy?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    In this panel discussion, Dr. Mark Socinski sits down with Dr. Benjamin Levy and Dr. Jyoti Patel to discuss the ways we can use PD-L1 status to identify when monotherapy or combination therapy is appropriate in patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC). 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mark A. Socinski, MD
    Executive Medical Director, Thoracic Cancer
    AdventHealth Medical Group
    Orlando, FL

    Dr. Socinski is a speaker for AstraZeneca, Celgene, Genentech, and Guardant Health and has contracted research with AstraZeneca, Genentech, and Spectrum.

    Benjamin Philip Levy, MD
    Clinical Director of Medical Oncology
    Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
    Associate Professor of Oncology
    Washington, DC

    Dr. Levy receives consulting fees from AstraZeneca, Celgene, Eli Lilly, Genentech, and Takeda.

    Jyoti D. Patel, MD
    Professor of Medicine
    Director, Thoracic Oncology
    University of Chicago
    Chicago, IL

    Dr. Patel receives consulting fees from AbbVie and AstraZeneca.

    Reviewers/Content Planners/Authors:

    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
    • William Mencia, MD, PhD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify patients with NSCLC who may benefit from immunotherapy monotherapy
    • Identify the appropriate forms of combination therapy in patients with mNSCLC with no identified driver mutations
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pathologists, and pulmonologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free